Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1Since this is a Phase 1/2 trial for SPG50, and the main thing being measured is whether the gene therapy causes serious or unexpected side effects (Grade 3 or higher toxicities), what does that mean for how much is currently known about its safety in people — and how does that uncertainty weigh against our options?
2. 2This trial uses a one-time AAV9 gene therapy to deliver a corrected copy of the AP4M1 gene — is my child's specific genetic mutation in AP4M1 the kind that this approach is designed to address, and would their age or disease progression affect whether they might be considered a candidate?
3. 3Given that AAV9-based gene therapies can sometimes trigger immune reactions, what monitoring or precautions does this trial have in place, and how would we respond if a serious reaction occurred?
4. 4Are there any standard-of-care treatments for SPG50 — like physical therapy, antispasticity medications, or other supportive care — that we should be pursuing now regardless of this trial, or that might be affected by participation?
5. 5Since this trial is actively recruiting, what would the practical demands look like for our family — things like how often we'd need to travel for visits, how long follow-up lasts, and what happens to my child's care if we need to withdraw?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.